Upexi, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2023, compared with fiscal year ended June 30, 2022. Although the request metadata refers to “2022 Q4,” this filing reports full fiscal years, not a standalone quarter.
Business context
Upexi is a multi-brand consumer products and distribution company focused on health, wellness, pet, beauty and toys. It reports Branded Products and Recommerce segments. Acquisitions of LuckyTail and E-Core expanded pet products, toys and wholesale distribution; the company describes a strategic shift toward distributing owned and non-owned brands. The filing reports 55% ownership of Cygnet at year-end; Upexi acquired the remaining 45% in September 2023.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $80.7 million | $23.1 million |
| Gross profit | $33.6 million | $14.9 million |
| Gross margin | 42% | 64% |
| Operating loss | $7.6 million | $6.5 million |
| Net loss attributable to Upexi | $16.9 million | $2.1 million |
| Adjusted EBITDA (non-GAAP) | $1.3 million | $(1.6) million |
| Cash at year-end | $4.5 million | $7.1 million |
- Revenue rose 250%; management attributed much of the increase to acquisitions. Recommerce generated $54.2 million and Branded Products $26.5 million. The filing notes lower-than-expected Amazon sales volume.
- Gross margin fell to 42%, mainly due to the larger share of lower-margin recommerce sales. Management expects margin improvement as branded products grow and purchasing scale increases.
- Cash provided by continuing operating activities was $0.5 million; investing activities used $2.6 million and financing activities used $0.3 million. Cash decreased by $2.7 million overall.
- Working capital was reported as $5.8 million at June 30, 2023, versus $6.9 million a year earlier. Current assets were $25.5 million and current liabilities $19.6 million.
- Debt carrying value, including convertible, acquisition and other notes, was approximately $25.9 million, excluding a $0.9 million line of credit. The filing also describes substantial acquisition-note payments due in FY2024; debt maturities and discounts warrant review.
Changes, outlook and material items
- Cost of revenue, sales and marketing, and distribution costs increased significantly alongside acquisitions and higher sales. Distribution costs were also affected by transportation and third-party provider rates. Management said it was adjusting pricing, promotions and packaging and consolidating distribution centers.
- Other expense included a $2.2 million loss related to the Infusionz asset sale, a $3.7 million impairment of Interactive Offers intangible assets, and higher interest expense. Interest expense, net, was $4.8 million versus $0.2 million in FY2022.
- Upexi sold Infusionz and certain manufacturing assets in October 2022. The buyer, Bloomios, did not meet certain obligations or complete the transition as expected. Upexi reserved amounts due and reported a $0.845 million net receivable from Bloomios at year-end; it valued its Bloomios investment at zero after reserves.
- After year-end, Upexi sold Interactive Offers for $1.25 million, subject to adjustments, plus a two-year share of certain advertising revenue. It also acquired the remaining Cygnet interest for cash, shares and a deferred payment.
- Management expects FY2024 revenue to increase, with emphasis on branded products. It estimated FY2024 interest expense below $2.8 million and cash interest below $1.4 million, and stated that working capital should suffice for operations and debt obligations over the following 12 months. These are forward-looking estimates, not guarantees.
- Key risks include evolving hemp/CBD regulation, competition and pricing pressure, supply and raw-material costs, acquisition integration, customer/channel concentration, product liability, and the company’s thinly traded stock.
Audit, controls and investor verification points
- The independent auditor issued an unqualified opinion on the financial statements, but did not audit or opine on internal control effectiveness.
- The filing contains conflicting statements about control effectiveness: one disclosure-controls conclusion says ineffective and another says effective; the internal-control discussion likewise includes both an effective conclusion and a later conclusion of ineffective with material weaknesses in segregation of duties and supervisory review. Management said remediation was planned, including additional qualified staff and a new ERP system.
- Verify the reported results and disclosures against the audited statements and subsequent filings, particularly the conflicting controls statements and the working-capital figure.
- Review debt agreements, cash requirements and FY2024 maturities, including acquisition notes and related-party borrowing; assess whether the company’s liquidity outlook remains achievable.
- Assess the quality and collectability of the Bloomios receivable and the basis for the zero valuation of Bloomios-related investments, as well as final proceeds and adjustments from the Interactive Offers sale.
- Separate acquisition-driven revenue growth from organic performance; examine Amazon sales trends, branded-product margins, inventory levels and customer concentration.
- Consider dilution: the company issued shares to fund acquisitions and interest, raised equity during FY2023, and had substantial outstanding options and remaining plan capacity.